UroGen Pharma Ltd (URGN)
14.22
-0.30
(-2.07%)
USD |
NASDAQ |
Apr 24, 16:00
14.22
0.00 (0.00%)
After-Hours: 18:43
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 485.22M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 44.62% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.956 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -1.511 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 92.16% |
Profile
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. |
URL | https://www.urogen.com |
Investor Relations URL | https://investors.urogen.com/ |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 14, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. |
URL | https://www.urogen.com |
Investor Relations URL | https://investors.urogen.com/ |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Mar. 14, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |